ResMed (RMD): Vanguard discloses 13.66% stake, 20.01M shares
The Vanguard Group filed an amended Schedule 13G reporting a passive stake in ResMed Inc. (RMD).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed an amended Schedule 13G reporting a passive stake in ResMed Inc. (RMD). As of 09/30/2025, Vanguard reported 20,007,417.40 shares beneficially owned, representing 13.66% of the class. The filing notes the holdings are in the form of depository receipts.
Vanguard reported 0 shares with sole voting power and 1,834,309.40 with shared voting power. It reported 17,643,708.00 shares with sole dispositive power and 2,363,709.40 with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. Its clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did The Vanguard Group report in ResMed (RMD)?
Is Vanguard’s filing for ResMed (RMD) passive or active?
What voting powers did Vanguard report for its ResMed (RMD) holdings?
What dispositive powers did Vanguard disclose for ResMed (RMD)?
Did Vanguard state any control intent regarding ResMed (RMD)?
Are Vanguard’s ResMed (RMD) holdings in depository receipts?
AI-generated analysis. How Rhea-AI works. Not financial advice.